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Patient preferences in the medical product lifecycle 
 
There is an emerging consensus that evidence on patients’ perspectives provides crucial guidance for 
decision-making throughout the medical product lifecycle (MPLC). Considering the patient voice has 
become increasingly important for developers of new medical products and for authorities that assess, 
regulate and decide which products are effective, safe, well tolerated and cost-effective [1, 2]. 
However, as key stakeholders, we lack a shared understanding about how to consider patient 
preferences in the MPLC [3]. 
 
This commentary captures opinions of thought leaders presenting at the symposium on “Patient 
preferences in the medical product lifecycle” in Basel, Switzerland in July 2019. The symposium was 
jointly sponsored by the International Academy of Health Preference Research (IAHPR; 
www.iahpr.org) and the research project ‘Patient Preferences in Benefit and Risk Assessments during 
the Treatment Life Cycle’ (PREFER; www.imi-prefer.eu). This commentary is one of a series of papers 
reporting on health preference research symposiums held alongside IAHPR meetings [4-6].  
 
At the symposium, a varied panel shared their experience as researchers, policy-makers, industry 
leaders and patients, on the use of patient preferences in the MPLC and spoke to the following six 
questions.  
 
1. Does patient preference information in reimbursement decision-making lead to higher quality 
decisions and increased public acceptance of decisions regarding allocation of healthcare 
resources?  
Although it is widely acknowledged that patient preferences contribute important evidence for 
reimbursement decisions, there are challenges in assessing its impact in decision-making.  First, there 
have not been enough published examples where preference studies have been submitted as part of 
the reimbursement process, on which to judge on their impact. Secondly, even where examples are 
available, the complexity of decision-making means it is difficult to single out the impact of preference 
information from the impact of other decision ‘inputs’ such as clinical and economic evidence and 
societal factors. Thirdly, preference studies are mostly undertaken late in the product development 
process. When this occurs, there may be a tendency to retro-fit the attributes to those which the 
product in question addresses, or which have been measured in the trials. There is the risk that such 
attributes are not addressing those things that matter most to the patient. The health technology 
assessment (HTA) body may well recognize this discrepancy [7]. Likewise, the patient voice might be 
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dampened if what matters to them is not addressed by the new product, with or without a preference 
study to support it. Fourth, where a preference study is sponsored by a manufacturer, there may be 
a perceived conflict of interest resulting in a high level of scrutiny, but also a potentially high and 
possibly inappropriate level of scepticism in their findings. 
 
Undertaking preference studies early in the development process is an opportunity to strengthen their 
impact on both the development process and reimbursement. There are examples where preference 
evidence has impacted decision-making and therefore potentially improved the ‘quality’ of decisions 
[8, 9]. As such, the panel were generally of the view that preference information will improve the 
quality of decisions, although less decided on whether the consideration of patient preference 
information increased public acceptance of decisions regarding allocation of healthcare resources. At 
least it has the potential to increase the transparency of the decision-making process, and there was 
general agreement that broader stakeholder involvement in the decision-making process was 
desirable.  
 
2. What should happen first to achieve successful integration of patient preference information 
into the MPLC?  
To date, successful integration of patient preference information into the medical product lifecycle 
has been slow, unsystematic, or very limited [10, 11]. To promote successful integration, it is necessary 
first to address the concerns of users of preference information. Publication of examples where 
preference information has been beneficial and creating projects that involve collaboration across 
stakeholders would also promote successful integration. For some conditions there are multiple 
companies with similar interests. Therefore collaboration between competing companies when 
undertaking studies would allow companies to pool resources and expertise, and reduce any 
perception of biased interests.  
 
Who should fund preference studies presents a dilemma. Regulators look to industry to generate good 
quality preference studies to support their decision-making [12]. However, pharmaceutical and 
medical technology companies may be averse to spending research resources to undertake studies 
that are not seen to influence regulators decisions. The uptake of preference studies and examples of 
impact might be expected to break this deadlock, even if progress is gradual initially. Finally, industry 
standards, research standards and quality guidelines for undertaking preference studies are needed 
to support the use of patient preferences in regulatory and HTA decisions. Text books in the field (such 
as that currently being developed by IAHPR), consensus guidance, and a more consistent approach to 
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developing protocols before undertaking a preference study should all assist the perceived rigour and 
therefore integration of preference studies. Rigour can be improved by adhering to an a priori study 
protocol; for example, via the HPSTR database [13], and reporting according to appropriate peer-
review standards such as those recommended by the ISPOR review task force [14] and through 
publication in a peer-reviewed journal. 
 
3. Which preference methods are most promising or acceptable to be used in regulatory 
assessments or reimbursement decision-making?  
As with any research area, the method needs to suit the research question. Currently, discrete choice 
experiments (DCEs) are perceived as the gold standard for evaluating preferences and are widely used. 
However, they are not suitable in all scenarios: when there are many attributes to consider (which 
may be the case in a new disease area in particular) or when patients might not be able to process a 
large amount of information being given to them. Also if the question relates to a rare disease, 
preference studies via DCEs may not reach a sufficient sample size to allow for valid statistical analyses 
and reliable preference data. In such circumstances, innovative approaches or other methods might 
be more suitable. 
 
The importance of using appropriate qualitative methods in the early stages of undertaking a 
preference study is now well established [9, 15, 16]. The development of consensus guidance to aid 
the selection of appropriate methods for different research questions was encouraged by the panel.  
 
4. At what point in the MPLC is patient preference information most useful, and for what purpose? 
Whilst funding can be challenging to obtain for preference studies, it may be easiest to obtain funding 
to elicit patient preference information during product development to support marketing, or for 
reimbursement decisions. Typically funding availability is greatest in the 12-24 months approaching 
product approval and launch, and is likely to be quite restricted early in the MPLC. However, 
consideration of patient preference evidence early and if feasible continuously in the product lifecycle 
can provide strong benefits for stakeholders. The net present value of engaging patients in the MPLC 
is high in the early phases of development [17]. The challenge is to secure the funding at this early 
stage of development. Once again, good examples of the impact of such early preference initiatives 
are needed in the literature to foster this shift of attention to earlier investment. Moreover, patient 
preference data may play an important role in designing trials [18], to help understand what risks and 
benefits should be measured and what effect size is meaningful for patients. It has also been shown 
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that trials can achieve faster recruitment and completion when patient input had been solicited during 
the design [19].  
 
Resources to undertake preference studies would be best directed to those products where 
preferences are most likely to influence the regulatory or reimbursement decisions. We need to 
understand the conditions and factors that make these decisions most sensitive to preferences [12], 
and should promote further research to help understand this. It is important for companies to have 
an early discussion with regulators and HTA bodies to both identify products for which patient 
preference information might be of particular benefit to decision-making, and to identify relevant 
effects for which risk-benefit trade-offs might be elicited, and to determine what constitutes patient 
value. Of note, the nuance between regulators and HTA agencies and the purpose for which they 
might use preference information also needs to be considered.  
 
5. Is there a role for use of preference information elicited from people other than patients to inform 
the MPLC?  
The decision problem and context are important considerations when deciding whose preferences are 
relevant. Where the general public are the payers for care, their preferences might be relevant for 
informing priorities about health and social care provision, and resource allocation at a population 
level (and this is typically done, for example through use of the EQ-5D and similar preference-based 
outcome measures).  
 
Once resources are allocated to a specific area, patient preferences on how to develop or prioritise 
treatments or products within that area become most relevant. Where patients are able to provide 
preferences every effort should be made to obtain preferences from patients themselves, or in some 
cases their caregivers, and the use of a proxy might not be acceptable. It is important to also remember 
that the relevant individuals to seek preferences from may differ in different cultural or geographical 
settings. This also raises the question of who is the ‘patient’? A patient preference study needs to 
clearly define the characteristics of the ‘patient’ of interest, using inclusion and exclusion criteria. 
Within a disease, people may have different characteristics, some of whom may be candidates for the 
drug based on the marketing authorisation or reimbursement criteria, others not. Further, 
participants within a clinical trial may be a very narrow subset of patients affected by the disease. For 
products targeting prevention, it may be service users or the general public rather than ‘patients’ that 
are most relevant. There is a continuum of ‘patients’, at one extreme is the general public, who are all 
potential service users, and at the other is an individual patient with a specific condition making an 
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individual decision about their treatment [20]. The patient population of interest will lie somewhere 
on this continuum.  
 
6. How might patient preference information best be elicited from patients and when? For example, 
is it acceptable (or even preferable) to elicit information alongside clinical trials?  
Eliciting preferences alongside a trial may be opportunistic. However, there are also arguments against 
eliciting preferences alongside a trial. Participants in a trial might be less risk-averse than other 
patients with the same condition. Whilst a trial may be helpful scientifically to accommodate 
randomisation and investigate comparative effects, it may not be the best setting for investigating 
preferences which would ideally be generalizable to the wider patient population. Preferences elicited 
alongside a clinical trial are also unlikely to give information on uptake by the broader patient 
population, which are useful particularly in the public health setting. If preferences are to be elicited 
alongside a trial, the timing of elicitation is important. Patients may be naïve to the product at the 
start of the trial, but some will be more familiar with the product by the end (though, they may be 
blinded to allocation). Product preferences may also be associated with trial drop-out, introducing a 
selection bias if preferences are elicited from participants later on in a trial.  
 
Concluding remarks 
To conclude, the symposium was unanimous about the important role of patient preference 
information  and that collecting preference data from an early stage of product development has clear 
benefits. There is a role for qualitative approaches to gather evidence on patient experiences and to 
inform the development of preference instruments. Qualitative evidence complements the quantified 
weights and trade-offs that preference information provides. Finally, it is important to recognise 
patient heterogeneity, in terms not only of defining the characteristics of the patient group of interest, 
but also of considering when in the patients journey is the most relevant time point to elicit 
preferences. 
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